Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts
Laura J. Janke(St. Jude Children's Research Hospital), Jerold E. Rehg(St. Jude Children's Research Hospital), Jiajie Xu(University of Michigan), Denise M. Imai(University of California, Davis), Kirsten Dickerson(St. Jude Children's Research Hospital), Zachary T. Freeman(University of Michigan), Charles G. Mullighan(St. Jude Children's Research Hospital), Portia S. Allen(University of Michigan), Ilaria Iacobucci(St. Jude Children's Research Hospital), Mark J. Hoenerhoff(University of Michigan), Heather Tillman(St. Jude Children's Research Hospital), Peter Vogel(Lexicon Pharmaceuticals (United States)), Rosalinda Doty(Jackson Laboratory), Natalie W. Fowlkes(The University of Texas MD Anderson Cancer Center)
Cited by 36
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells
|The Journal of Experimental Medicine|2011|1.8k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k